Experience of using a combined melatonin-containing drug in the correction of sleep disorders in women
Stenyaeva N.N., Khritinin D.F., Stenyaev E.Yu.
A review of existing research suggests that women are more likely to experience sleep disorders than men. Chronic sleep deprivation results in the activation of the hypothalamic-pituitary system and sympathetic nervous system, which increases the risk of menstrual disorders, ovarian dysfunction, spontaneous abortion, decreased ovarian reserve in women over 35 years of age, and low effectiveness of in vitro fertilization in women with infertility. Sleep disorders such as hypersomnia and insomnia associated with premenstrual syndrome and premenstrual dysphoric disorder have been described. Sleep disorders in women with polycystic ovary syndrome are almost twice as common as in healthy women of the same age. Insomnia is a common complaint in menopausal transition period and in postmenopause in more than half of women.
The results of numerous studies emphasize the importance of diagnostics and treatment of sleep disorders for effective correction of the underlying disease that leads to reproductive impairment and reduced quality of life in women.
The first-line drug choice in the treatment of insomnia are herbal sedatives and melatonin. Melatonin is a pleiotropic hormone, produced by the epiphysis, that regulates the circadian and seasonal rhythms of physiological functions of the body. It affects not only sleep-wake cycles, but also neuronal development, metabolic processes, protection and regulation of the immune, endocrine and reproductive systems.
SonNorm Duo is a combined drug containing melatonin, peppermint leaf oil and motherwort herb extract, which has adaptogenic and sedative effect, helps to reduce the nervous system excitability, reduce anxiety and excitement, improve sleep quality; it also normalizes circadian rhythms, including the sleep-wakefulness cycle and adaptation of weather-sensitive people to weather changes. Due to the gradual release of its components, SonNorm Duo has a higher clinical efficacy relative to mono-melatonin-containing drugs, as well as a high safety profile, and can be used with hormone therapy.
Conclusion: The use of the combined drug SonNorm Duo in clinical practice confirms its efficacy and safety in women of reproductive and menopausal age.
Authors' contributions: Stenyaeva N.N. – review of publications on the topic of the article, analysis of the data obtained, formation of an article plan, writing the text of the manuscript; Khritinin D.F. – editing and analysis of the obtained data; Stenyaev E.Yu. – data collection.
Conflicts of interest: The authors declare no possible conflicts of interest.
Funding: The study was conducted without sponsorship.
Patient Consent for Publication: The patients provided an informed consent for the publication of their data.
For citation: Stenyaeva N.N., Khritinin D.F., Stenyaev E.Yu. Experience of using a combined melatonin-containing drug in the correction of sleep disorders in women.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2024; (6): 154-160 (in Russian)
https://dx.doi.org/10.18565/aig.2024.138
Keywords
sleep
insomnia
sleep disorders
premenstrual syndrome
polycystic ovary syndrome
menopause
melatonin
motherwort
herbal sedatives
References
- Iranzo A. An overview on sleep medicine. Adv. Exp. Med. Biol. 2022; 1384: 3-15. https://dx.doi.org/10.1007/978-3-031-06413-5_1.
- Zeng L.N., Zong Q.Q., Yang Y., Zhang L., Xiang Y.F., Ng C.H. et al. Gender difference in the prevalence of insomnia: a meta-analysis of observational studies. Front. Psychiatry. 2020; 11: 577429. https://dx.doi.org/10.3389/fpsyt.2020.577429
- Frange C., Banzoli C.V., Colombo A.E., Siegler M., Coelho G., Bezerra A.G. et al. Women's sleep disorders: integrative care. Sleep Sci. 2017; 10(4): 174-80. https://dx.doi.org/10.5935/1984-0063.20170030.
- Kaltsouni E., Schmidt F., Zsido R.G., Eriksson A., Sacher J., Sundström-Poromaa I. et al. Electroencephalography findings in menstrually-related mood disorders: a critical review. Front. Neuroendocrinol. 2024; 72: 101120. https://dx.doi.org/10.1016/j.yfrne.2023.101120.
- Han K.S., Kim L., Shim I. Stress and sleep disorder. Exp. Neurobiol. 2012; 21(4): 141-50. https://dx.doi.org/10.5607/en.2012.21.4.141.
- Li Q.L., Wang C., Cao K.X., Zhang L., Xu Y.S., Chang L. et al. Sleep characteristics before assisted reproductive technology treatment predict reproductive outcomes: a prospective cohort study of Chinese infertile women. Front. Endocrinol. (Lausanne). 2023; 14: 1178396. https://dx.doi.org/10.3389/fendo.2023.1178396.
- Gong M., Gao Y., Wang Z., Lu F., Dong H. The impact of chronic insomnia disorder on menstruation and ovarian reserve in childbearing-age women: a cross-sectional study Clin. Exp. Reprod. Med. 2024; 51(2): 142-50. https://dx.doi.org/10.5653/cerm.2023.06513.
- Zafari Zangeneh F. Deregulated brain's central clock management on sleep-wake behavior in women with polycystic ovary syndrome: melatonin & sleep pattern. J. Family Reprod. Health. 2022; 16(4): 229-38. https://dx.doi.org/10.18502/jfrh.v16i4.11348.
- Patel A., Dewani D., Jaiswal A., Yadav P., Reddy L.S. Exploring melatonin's multifaceted role in polycystic ovary syndrome management: a comprehensive review. Cureus. 2023; 15(11): e48929. https://dx.doi.org/10.7759/cureus.48929.
- Hachul H., Polesel D.N., Tock L., Carneiro G., Pereira A.Z., Zanella M.T. et al. Sleep disorders in polycystic ovary syndrome: influence of obesity and hyperandrogenism. Rev. Assoc. Med. Bras. (1992). 2019; 65(3): 375-83. https://dx.doi.org/10.1590/1806-9282.65.3.375.
- Helvaci N., Karabulut E., Demir A.U., Yildiz B.O. Polycystic ovary syndrome and the risk of obstructive sleep apnea: a meta-analysis and review of the literature. Endocr. Connect. 2017; 6(7): 437-45. https://dx.doi.org/10.1530/EC-17-0129.
- Song S.O., He K., Narla R.R., Kang H.G., Ryu H.U., Boyko E.J. Metabolic consequences of obstructive sleep apnea especially pertaining to diabetes mellitus and insulin sensitivity. Diabetes Metab. J. 2019; 43(2): 144-55. https://dx.doi.org/10.4093/dmj.2018.0256.
- Salari N., Hasheminezhad R., Hosseinian-Far A., Rasoulpoor S., Assefi M., Nankali S. et al. Global prevalence of sleep disorders during menopause: a meta-analysis. Sleep Breath. 2023; 27(5): 1883-97. https://dx.doi.org/10.1007/s11325-023-02793-5.
- Cipolla-Neto J., Amaral F.G., Soares J.M. Jr., Gallo C.C., Furtado A., Cavaco J.E. et al. The crosstalk between melatonin and sex steroid hormones. Neuroendocrinology. 2022; 112(2): 115-29. https://dx.doi.org/10.1159/000516148.
- Ferlazzo N., Andolina G., Cannata A., Costanzo M.G., Rizzo V., Currò M. et al. Is melatonin the cornucopia of the 21st century? Antioxidants (Basel). 2020; 9(11): 1088. https://dx.doi.org/10.3390/antiox9111088.
- Olcese J.M. Melatonin and female reproduction: an expanding universe. Front. Endocrinol. (Lausanne). 2020; 11: 85. https://dx.doi.org/10.3389/fendo.2020.00085.
- Buysse D.J., Reynolds C.F. 3rd, Monk T.H., Berman S.R., Kupfer D.J. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989; 28(2): 193-213. https://dx.doi.org/10.1016/0165-1781(89)90047-4.
- Морозова М.А., Потанин С.С., Бениашвили А.Г., Бурминский Д.С., Лепилкина Т.А., Рупчев Г.Е., Кибитов А.А. Валидация русскоязычной версии Госпитальной шкалы тревоги и депрессии в общей популяции. Профилактическая медицина. 2023; 26(4): 7‑14. [Morozova M.A., Potanin S.S., Beniashvili A.G., Burminsky D.S., Lepilkina T.A., Rupchev G.E., Kibitov A.A. Validation of the Hospital Anxiety and Depression Scale Russian-language version in the general population. Russian Journal of Preventive Medicine. 2023; 26(4): 7-14. (in Russian)]. https://dx.doi.org/10.17116/profmed2023260417.
- Стеняева Н.Н., Хритинин Д.Ф., Стеняев Е.Ю. Менопауза и нарушения сна. Медицинский Совет. 2023; (15): 119-24. [Stenyaeva N.N., Khritinin D.F., Stenyaev E.Y. Menopause and sleep disturbances. Medical Council. 2023; (15): 119-24. (in Russian)]. https://dx.doi.org/10.21518/ms2023-333.
- Baglioni C., Bostanova Z., Bacaro V., Benz F., Hertenstein E., Spiegelhalder K. et al. A systematic review and network meta-analysis of randomized controlled trials evaluating the evidence base of melatonin, light exposure, exercise, and complementary and alternative medicine for patients with insomnia disorder. J. Clin. Med. 2020; 9(6): 1949. https://dx.doi.org/10.3390/jcm9061949.
- Alqutub S.T., Alzahran F.A., Hassan A.S., Alirbidi A.H., Alraddadi O.A., AlSadah O.A. et al. Exogenous melatonin use in university students: a cross-sectional survey. Pharmacy (Basel). 2024; 12(2): 41. https://dx.doi.org/10.3390/pharmacy12020041.
- Tahir S., Flynn K., Babiker M.O.E. Efficacy of melatonin as a sleep inducer in eeg procedures in the pediatric population: a cross-sectional study. Cureus. 2024; 16(2): e54196. https://dx.doi.org/10.7759/cureus.54196.
- Jones C.W., Larson O., Basner M., Dinges D.F. The dynamic responses of mood and sleep physiology to chronic sleep restriction and subsequent recovery sleep. Sleep. 2024: zsae091. https://dx.doi.org/10.1093/sleep/zsae091.
- Megha K.B., Arathi A., Shikha S., Alka R., Ramya P., Mohanan P.V. Significance of melatonin in the regulation of circadian rhythms and disease management. Mol. Neurobiol. 2024 Jan 11. https://dx.doi.org/10.1007/s12035-024-03915-0.
- Bocheva G., Bakalov D., Iliev P., Tafradjiiska-Hadjiolova R. The vital role of melatonin and its metabolites in the neuroprotection and retardation of brain aging. Int. J. Mol. Sci. 2024; 25(10): 5122. https://dx.doi.org/10.3390/ijms25105122.
- Zarezadeh M., Barzegari M., Aghapour B., Adeli S., Khademi F., Musazadeh V. et al. Melatonin effectiveness in amelioration of oxidative stress and strengthening of antioxidant defense system: Findings from a systematic review and dose-response meta-analysis of controlled clinical trials. Clin. Nutr. ESPEN. 2022; 48: 109-20. https://dx.doi.org/10.1016/j.clnesp.2022.01.038.
- De Simone M., De Feo R., Choucha A., Ciaglia E., Fezeu F. Enhancing sleep quality: assessing the efficacy of a fixed combination of linden, hawthorn, vitamin B1, and melatonin. Med. Sci. (Basel). 2023; 12(1): 2. https://dx.doi.org/10.3390/medsci12010002.
- Котова О.В., Акарачкова Е.С., Беляев А.А., Бородулина И.В., Павлова С.В. Эффективность и безопасность комбинированного препарата СонНорм Дуо у пациентов с инсомнией: результаты открытого рандомизированного сравнительного клинического исследования. Эффективная фармакотерапия. 2022; 18(36): 78-83. [Kotova O.V., Akarachkova E.S., Belyaev A.A., Borodulina I.V., Pavlova S.V. Efficacy and safety of the combined drug SonNorm Duo in patients with insomnia: results of an open randomized comparative clinical trial. Effective Pharmacotherapy. 2022; 18(36): 78-83. (in Russian)]. https://dx.doi.org/10.33978/2307-3586-2022-18-36-78-83.
- Dodda B.R., Bondi C.D., Hasan M., Clafshenkel W.P., Gallagher K.M., Kotlarczyk M.P. et al. Co-administering melatonin with an estradiol-progesterone menopausal hormone therapy represses mammary cancer development in a mouse model of HER2-positive breast cancer. Front. Oncol. 2019; 9: 525. https://dx.doi.org/10.3389/fonc.2019.00525.
Received 10.06.2024
Accepted 20.06.2024
About the Authors
Natalya N. Stenyaeva, Ph.D., Senior Researcher at the Department of Andrology and Urology, Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, 117997, Russia, Moscow, Aс. Oparina str., 4, +7(903)538-03-34, nataliasten@mail.ru,https://orcid.org/0000-0002-6495-3367
Dmitry F. Khritinin, Corresponding Member of RAS, Dr. Med. Sci., Professor at the Department of Psychiatry and Narcology, Faculty of Medicine, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University), 119991, Russia, Moscow, Trubetskaya str., 8-2, +7(495)609-14-00,
https://orcid.org/0000-0001-9107-2357
Evgeny Yu. Stenyaev, 6th year student of the Medical Faculty of Foreign Students, Belarusian State Medical University, Minsk, +7(905)579-73-81,
https://orcid.org/0009-0001-9301-7535
Similar Articles
